(March 10, 2020) Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus DiseaseGAITHERSBURG, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Novavax, Inc. (NASDAQ:NVAX)
whereby Emergent will collaborate with Novavax, utilizing its molecule-to-market contract development and manufacturing (CDMO) services
to support bringing into the clinic Novavax’s novel experimental vaccine candidate
to protect against coronavirus disease (COVID-19). Under the terms of the agreement,
Emergent will produce the COVID-19 experimental vaccine candidate, which is based on the proprietary recombinant protein nanoparticle technology platform of Novavax
and utilizing their proprietary Matrix-M™ adjuvant to enhance immune responses.
Emergent has initiated work for this program anticipating that the COVID-19 experimental vaccine candidate
will be used in a Phase 1 clinical study within the next four months.
[
link to www.globenewswire.com (secure)]
(August 16, 2020) Novavax, partnering with Morrisville firm, lands Covid-19 vaccine deal with U.K.Novavax Inc. has locked in a deal to provide 60 million doses of its Covid-19 vaccine to the United Kingdom,
the latest of multiple agreements the Maryland biotech has inked in the past week. Deal terms were not disclosed.
Novavax (Nasdaq: NVAX) said it will expand its partnership with Tokyo-based Fujifilm Diosynth Biotechnologies
to make the antigen for its candidate, NVX-CoV2373, including 180 million doses at the latter’s U.K. site each year.
That expanded supply would serve additional markets, Novavax said Friday.
The company plans to start supplying doses to the U.K. as early as the first quarter of 2021.
The company also secured agreements with Fujifilm, Emergent BioSolutions Inc. (NYSE: EBS),
AGC Biologics and PolyPetide Group; acquired Praha Vaccines and its Czech manufacturing facility for $167 million;
and made several executive hires, including appointing David Mott to its board of directors.
[
link to www.researchtriangle.org (secure)]